{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:49:07Z","timestamp":1792273747199,"version":"4.4.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T00:00:00Z","timestamp":1434585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0130277","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T18:17:18Z","timestamp":1434651438000},"page":"e0130277","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":53,"title":["Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells"],"prefix":"10.1371","volume":"10","author":[{"given":"Markus","family":"Hecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Erber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Parsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luitpold V.","family":"Distel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,6,18]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","article-title":"Life expectancy living with HIV: recent estimates and future implications","volume":"26","author":"F Nakagawa","year":"2013","journal-title":"Current opinion in infectious diseases"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/596766","article-title":"Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey","volume":"48","author":"F Bonnet","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"13","key":"ref3","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/QAD.0b013e3283625444","article-title":"Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system","volume":"27","author":"M Hecht","year":"2013","journal-title":"AIDS"},{"issue":"24","key":"ref4","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1038\/sj.onc.1208562","article-title":"Inhibition of endogenous reverse transcriptase antagonizes human tumor growth","volume":"24","author":"I Sciamanna","year":"2005","journal-title":"Oncogene"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1210\/jc.2005-0367","article-title":"Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma","volume":"90","author":"M Landriscina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"ref6","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1038\/sj.onc.1206354","article-title":"Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation","volume":"22","author":"R Mangiacasale","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1590\/S1677-55382008000400012","article-title":"In vitro evidence for a new therapeutic approach in renal cell carcinoma","volume":"34","author":"C Pittoggi","year":"2008","journal-title":"Int Braz J Urol"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.18632\/oncotarget.1403","article-title":"A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines","volume":"4","author":"I Sciamanna","year":"2013","journal-title":"Oncotarget"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gcc.20266","article-title":"A role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy","volume":"45","author":"P Sinibaldi-Vallebona","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ygyno.2008.08.006","article-title":"Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells","volume":"111","author":"K Stefanidis","year":"2008","journal-title":"Gynecologic oncology"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jhep.2013.06.005","article-title":"ER stress in human hepatic cells treated with Efavirenz: mitochondria again","volume":"59","author":"N Apostolova","year":"2013","journal-title":"Journal of hepatology"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1476-5381.2010.00866.x","article-title":"Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells","volume":"160","author":"N Apostolova","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.antiviral.2012.04.003","article-title":"Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz","volume":"94","author":"LJ Gomez-Sucerquia","year":"2012","journal-title":"Antiviral research"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/095530098141807","article-title":"Analysis of radiation- and 5-FU-induced inhibition of cell proliferation by an automatic colony analyser","volume":"74","author":"A Piasecka","year":"1998","journal-title":"Int J Radiat Biol"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.bloodjournal8451415","article-title":"Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis","volume":"84","author":"G Koopman","year":"1994","journal-title":"Blood"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","article-title":"Phenotype and genotype of pancreatic cancer cell lines","volume":"39","author":"EL Deer","year":"2010","journal-title":"Pancreas"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"e26739","DOI":"10.1371\/journal.pone.0026739","article-title":"Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection","volume":"6","author":"J Wang","year":"2011","journal-title":"PloS one"},{"issue":"5","key":"ref18","first-page":"551","article-title":"Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations","volume":"39","author":"LF Lopez-Cortes","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"14","key":"ref19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/01.aids.0000183630.27665.30","article-title":"Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin","volume":"19","author":"W Manosuthi","year":"2005","journal-title":"Aids"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"C Marzolini","year":"2001","journal-title":"AIDS"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"F Gutierrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/1874613601206010266","article-title":"Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women","volume":"6","author":"W Ratanasuwan","year":"2012","journal-title":"The open AIDS journal"},{"issue":"2","key":"ref23","first-page":"135","article-title":"Influence of rifampicin on nevirapine plasma concentration in HIV-TB coinfected patients","volume":"44","author":"Nafrialdi","year":"2012","journal-title":"Acta medica Indonesiana"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3851\/IMP1562","article-title":"Pharmacokinetics of once-daily etravirine without and with once-daily darunavir\/ritonavir in antiretroviral-naive HIV type-1-infected adults","volume":"15","author":"E DeJesus","year":"2010","journal-title":"Antiviral therapy"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1468-1293.2008.00668.x","article-title":"Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers","volume":"10","author":"TN Kakuda","year":"2009","journal-title":"HIV Med"},{"issue":"17","key":"ref26","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1097\/00002030-200311210-00011","article-title":"A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects","volume":"17","author":"B Gruzdev","year":"2003","journal-title":"AIDS"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1128\/AAC.05194-11","article-title":"No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects","volume":"56","author":"M Vourvahis","year":"2012","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1128\/AAC.01110-09","article-title":"Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine","volume":"54","author":"M Vourvahis","year":"2010","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1128\/AAC.00572-11","article-title":"Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects","volume":"56","author":"M Vourvahis","year":"2012","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jac\/dkh252","article-title":"Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers","volume":"54","author":"US Justesen","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0009-9236(97)90133-8","article-title":"Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test","volume":"61","author":"CL Cheng","year":"1997","journal-title":"Clinical pharmacology and therapeutics"},{"issue":"13","key":"ref32","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/01.aids.0000242818.65215.bd","article-title":"Short-term antiviral activity of TMC278\u2014a novel NNRTI\u2014in treatment-naive HIV-1-infected subjects","volume":"20","author":"F Goebel","year":"2006","journal-title":"AIDS"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1128\/AAC.01235-13","article-title":"Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744","volume":"57","author":"SL Ford","year":"2013","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"H Azijn","year":"2010","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1128\/AAC.01455-09","article-title":"Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1","volume":"54","author":"R Corbau","year":"2010","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/095632029901000601","article-title":"Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom","volume":"10","author":"OS Pedersen","year":"1999","journal-title":"Antiviral chemistry & chemotherapy"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2091-12-18","article-title":"Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition","volume":"12","author":"L Dai","year":"2011","journal-title":"BMC biochemistry"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"e1547","DOI":"10.1371\/journal.pone.0001547","article-title":"Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition","volume":"3","author":"RB Jones","year":"2008","journal-title":"PloS one"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1476-4598-12-145","article-title":"High mitochondria content is associated with prostate cancer disease progression","volume":"12","author":"K Grupp","year":"2013","journal-title":"Molecular cancer"},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/cncr.21334","article-title":"Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals","volume":"104","author":"A Burgi","year":"2005","journal-title":"Cancer"},{"issue":"16","key":"ref41","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/QAD.0b013e328331d384","article-title":"Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy","volume":"23","author":"MT van Leeuwen","year":"2009","journal-title":"AIDS"},{"issue":"17","key":"ref42","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/QAD.0b013e32835935b3","article-title":"Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons","volume":"26","author":"C Chao","year":"2012","journal-title":"Aids"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Adler DH, Kakinami L, Modisenyane T, Tshabangu N, Mohapi L, De Bruyn G, et al. Increased regression and decreased incidence of HPV-related cervical lesions among HIV-infected women on HAART. Aids. 2012. <object-id pub-id-type=\"pmid\">22555167<\/object-id>.","DOI":"10.1097\/QAD.0b013e32835536a3"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/QAD.0b013e328340fd99","article-title":"Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort","volume":"25","author":"T Omar","year":"2011","journal-title":"Aids"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2014-0345","article-title":"A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer","volume":"19","author":"N Houede","year":"2014","journal-title":"The oncologist"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(06)70908-1","article-title":"Cell differentiation and iodine-131 uptake in poorly differentiated thyroid tumour in response to nevirapine","volume":"7","author":"M Landriscina","year":"2006","journal-title":"The Lancet Oncology"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/cbr.2006.316","article-title":"Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine","volume":"22","author":"S Modoni","year":"2007","journal-title":"Cancer biotherapy & radiopharmaceuticals"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/blood-2008-06-162289","article-title":"Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone","volume":"112","author":"JE Amengual","year":"2008","journal-title":"Blood"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-0609.2004.00339.x","article-title":"HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy alone","volume":"74","author":"T Girard","year":"2005","journal-title":"Eur J Haematol"},{"issue":"6","key":"ref50","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jjco\/hyi093","article-title":"A long-term survival case of small cell lung cancer in an HIV-infected patient","volume":"35","author":"T Kato","year":"2005","journal-title":"Jpn J Clin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0130277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T19:57:36Z","timestamp":1599163056000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0130277"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,18]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0130277","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,18]]}}}